Samy Metyas, MD
Rheumatology · Covina, CANPI 1831104694
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $982,316 of the $1,278,502 with a category attached, or 76.8%. 55 manufacturers reported payments, led by Amgen at 30.3% of the total. Among rheumatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,107 payments — averaging $411.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$387K
- AbbVie$208K
- Lilly USA, LLC$149K
- Johnson & Johnson$103K
- Mallinckrodt Hospital Products Inc.$97K
- UCB, Inc.$69K
- plus $266K from 49 others
Across 895 payments — averaging $13,029 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$6.7M
- Eli Lilly$1.2M
- Novartis$1.1M
- AbbVie$630K
- GSK$505K
- Gilead$433K
- plus $1.2M from 21 others
What the payments were for
- Consulting fees$109,8069%
- Speaking & faculty fees$982,31677%
- Travel & lodging$122,61510%
- Food & beverage$62,6745%
- Education$1,0330%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,278,502 in reported general payments places this provider in the 95th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProliaDenosumab | 784 | $1,248,509 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 48 | $868,766 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 28 | $641,985 |
| Cimzia (2 Pack)Certolizumab Pegol | 94 | $629,592 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 247 | $590,152 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 36 | $586,258 |
| RinvoqUpadacitinib | 78 | $507,873 |
| RemicadeInfliximab | 75 | $421,475 |
| Humira(Cf) PenAdalimumab | 28 | $394,619 |
| TremfyaGuselkumab | 30 | $393,289 |
| OrenciaAbatacept/Maltose | 85 | $364,870 |
| Enbrel SureclickEtanercept | 33 | $311,097 |
| KevzaraSarilumab | 63 | $276,893 |
| OtezlaApremilast | 60 | $253,359 |
| RenflexisInfliximab-Abda | 64 | $214,525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenProlia, Evenity (2 Syringes), Otezla, Enbrel, Rayos | $386,966 | $2,345,1961,152 claims |
| Johnson & JohnsonRemicade, Tremfya, Simponi Aria | $102,634 | $974,898125 claims |
| PfizerOctagam, Xeljanz, Inflectra | $1,275 | $755,53971 claims |
| UCB, Inc.Cimzia (2 Pack) | $68,781 | $629,59294 claims |
| AbbVieRinvoq, Savella | $208,327 | $539,586124 claims |
| E.r. Squibb & Sons, L.L.C.Orencia, Orencia | $3,100 | $502,80699 claims |
| SanofiKevzara | $44,467 | $276,89363 claims |
| OrganonRenflexis | $599 | $214,52564 claims |
| GSKBenlysta | $1,442 | $204,68455 claims |
| Boehringer IngelheimOfev | $3,309 | $172,29114 claims |
| NovartisCosentyx | $38,070 | $155,08641 claims |
| AstraZenecaSaphnelo | $9,393 | $98,74519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 808 rheumatology providers in California.
Other rheumatology in Covina
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
- Roger KornuTustin$802K
- Arthur Kavanaughla Jolla$756K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.